News

The transaction, subject to regulatory approval and other customary closing conditions, is expected to close by the first quarter of 2015. Over the past seven years, KU has

Results were presented in a poster presentation entitled "Novel synthetic RORgamma agonist compounds as a potential anti-tumor therapeutic approach" and will be highlighted in an oral presentation on

As part of this collaboration, Idera and PPMD intend to work together to conduct preclinical studies and develop a clinical development strategy for an investigational TLR antagonist candidate.

ORSL is a fruit-based drink useful for electrolytes restoration during mild dehydration and general disability. It is generally used following cough & cold, pain, fever and other digestive

The trial showed that these patients with the most common type of EGFR mutation, (exon 19 deletion; del19), lived significantly longer after receiving first-line treatment with afatinib compared

Staphefekt is the first endolysin available for human use on intact skin. Endolysins are enzymes that originate from bacteriophages (phages), microorganisms that kill only bacteria. In nature, phages

The NDA supports the use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. The company

University of California associate professor of Neurological Surgery and principal investigator of the study Dr Nicholas Butowski is sponsoring and conducting the Phase I trial and it is

SPK-RPE65 targets a group of blinding conditions known as inherited retinal dystrophies (IRDs). IRDs are caused by autosomal recessive mutations in the RPE65 gene, for which currently there